ES2058420T3 - Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos. - Google Patents

Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos.

Info

Publication number
ES2058420T3
ES2058420T3 ES89114818T ES89114818T ES2058420T3 ES 2058420 T3 ES2058420 T3 ES 2058420T3 ES 89114818 T ES89114818 T ES 89114818T ES 89114818 T ES89114818 T ES 89114818T ES 2058420 T3 ES2058420 T3 ES 2058420T3
Authority
ES
Spain
Prior art keywords
antineoplasic
medicines
pharmaceutical preparations
combined pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89114818T
Other languages
English (en)
Inventor
Hans Hermann Prof Grunicke
Dieter Dr Med Herrmann
Johann Dr Hofmann
Elmar Dr Phil Nat Bosies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6361067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2058420(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Application granted granted Critical
Publication of ES2058420T3 publication Critical patent/ES2058420T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A UN PREPARADO FARMACEUTICO QUE SE EMPLEA EN LA TERAPIA ANTINEOPLASTICA. EL PREPARADO CONTIENE UNA MATERIA ACTIVA LOS COMPUESTOS DE PROTEINOQUINASA C HUMANA COMBINADOS CON GRASAS, LIPIDOS, CITOSTATICA O COMPUESTOS QUE INHIBEN LA FOSFOLIPASA.
ES89114818T 1988-08-18 1989-08-10 Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos. Expired - Lifetime ES2058420T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827974A DE3827974A1 (de) 1988-08-18 1988-08-18 Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen

Publications (1)

Publication Number Publication Date
ES2058420T3 true ES2058420T3 (es) 1994-11-01

Family

ID=6361067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89114818T Expired - Lifetime ES2058420T3 (es) 1988-08-18 1989-08-10 Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos.

Country Status (17)

Country Link
US (2) US5578590A (es)
EP (1) EP0359981B1 (es)
JP (1) JPH02108636A (es)
KR (1) KR900002784A (es)
AT (1) ATE91903T1 (es)
AU (1) AU627207B2 (es)
CA (1) CA1330035C (es)
DD (1) DD283938A5 (es)
DE (2) DE3827974A1 (es)
DK (1) DK401089A (es)
ES (1) ES2058420T3 (es)
HU (1) HUT52396A (es)
IE (1) IE64635B1 (es)
IL (1) IL91343A (es)
NZ (1) NZ230323A (es)
PT (1) PT91470A (es)
ZA (1) ZA896287B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA908936B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with quinolyloxazole-2-ones
ZA908852B (en) * 1989-11-13 1991-09-25 Merrell Dow Pharma Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones
EP0507938A4 (en) * 1990-11-02 1993-03-10 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
DE69221069T2 (de) * 1991-05-14 1997-11-13 Merrell Pharma Inc Hemmung von metastasen bei krebspatienten mit pyridyloxazol-2-onen
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5270310A (en) * 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5292737A (en) * 1992-10-23 1994-03-08 Sphinx Pharmaceuticals Corporation N,N'-bis(sulfonamido)-2-amino-4-iminonaphthalen-1-ones and N,N'-bis(amido)-2-amino-4-iminonaphthalen-1-ones
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
EP0643966A4 (en) * 1993-03-03 1995-08-09 Kyowa Hakko Kogyo Kk SENSITIVITY BOOSTER FOR ANTINEOPLASTIC AGENT.
GB9509572D0 (en) * 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
JP3565003B2 (ja) 1998-04-02 2004-09-15 日産自動車株式会社 自動車の排水構造
DE19959689A1 (de) * 1998-12-04 2000-06-08 Max Delbrueck Centrum Mittel zur Tumortherapie
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
CA2492059A1 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
DK2447252T3 (da) * 2004-05-23 2020-03-16 Hmi Medical Innovations Llc Theramuteinmodulatorer
ES2246165B1 (es) * 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8431110B2 (en) * 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
KR101347100B1 (ko) 2005-07-29 2014-01-03 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
US20070112053A1 (en) 2005-09-16 2007-05-17 Pickett Cecil B Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
CN103789389B (zh) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP2091520B1 (en) * 2006-11-10 2012-02-22 Alphaptose Gmbh Oral dosage form comprising tri-substituted glycerol compounds
JP5512275B2 (ja) * 2006-11-10 2014-06-04 ラディオプロテクト アルファプトーゼ ウーゲー（ハフツングスベシュレンクト） ウント コー．カーゲー 放射線傷害治療のための三置換グリセロール化合物の使用
EP3332797A3 (en) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
CA2952953C (en) * 2014-06-19 2024-01-23 Quercegen Pharmaceuticals Llc Method for treating cancer with a combination of quercetin and a chemotherapy agent
WO2019169389A1 (en) * 2018-03-02 2019-09-06 Epicentrx, Inc. Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
US11872241B2 (en) 2018-11-30 2024-01-16 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001506A1 (en) * 1982-10-13 1984-04-26 Univ Birmingham Pharmaceutical preparations for use in antitumour therapy
EP0409845A4 (en) * 1988-02-23 1991-07-03 U.S. Bioscience Method for protection from chemotherapeutic side effects
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0359981A1 (de) 1990-03-28
DE3827974A1 (de) 1990-02-22
IL91343A0 (en) 1990-03-19
PT91470A (pt) 1990-03-08
JPH02108636A (ja) 1990-04-20
KR900002784A (ko) 1990-03-23
DE58905028D1 (de) 1993-09-02
DD283938A5 (de) 1990-10-31
AU627207B2 (en) 1992-08-20
IL91343A (en) 1996-05-14
EP0359981B1 (de) 1993-07-28
US5578590A (en) 1996-11-26
IE892646L (en) 1990-02-18
IE64635B1 (en) 1995-08-09
DK401089A (da) 1990-02-19
ZA896287B (en) 1990-05-30
US5770593A (en) 1998-06-23
ATE91903T1 (de) 1993-08-15
NZ230323A (en) 1992-05-26
HUT52396A (en) 1990-07-28
CA1330035C (en) 1994-06-07
AU3955089A (en) 1990-02-22
DK401089D0 (da) 1989-08-15

Similar Documents

Publication Publication Date Title
ES2058420T3 (es) Preparados farmaceuticos combinados y su utilizacion como medicamentos antineoplasicos.
DE3883035D1 (de) Saponinkomplexe mit phospholipiden und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
DK393187A (da) Laegemiddel med antitumorvirkning
DE3875425D1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
GR3007202T3 (es)
DE3685094D1 (de) Pharmazeutisches praeparat zur kontrollierten freisetzung von wirkstoffen.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
ATE234082T1 (de) Adenosin enthaltendes arzneimittel
ES2058988T3 (es) Preparacion de medicamentos para el tratamiento sistemico de peces ornamentales y utiles.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
MX9301746A (es) Nuevos acidos 9-fluor-7-oxo-7h-pirido(1,2,3,-de)(1,4)-benzoxacin-6-carboxilicos y sus esteres, procedimiento para su preparacion y medicamentos que los contienen.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
SE8403659L (sv) Synergistiska farmaceutiska kompositioner
NO882065D0 (no) Diarylalkyl-substituerte alkylaminer, fremgangsmaate til deres fremstilling, deres anvendelse, samt legemidler som inneholder denne.
NO165542C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner.
IT8020100A0 (it) Medicamento, o preparato farmaceutico, ad azione citostatica.
DK139685A (da) Liposomer med inhalative allergener til behandling af allergier, fremgangsmaade til deres fremstilling og laegemidler indeholdende disseliposomer
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
DE3877747D1 (de) Glasartige matrize zur verabreichung von heilmitteln.
MX9203589A (es) Acido(cicloalquilamino)metileno-bis(fosfonico) y medicinas que lo contienen como ingrediente activo.
DE3579140D1 (de) Arzneimittel mit einem 6-substituierten adenosin als aktives bestandteil.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 359981

Country of ref document: ES